{"id":"inpegsomatropin-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inpegsomatropin is a pegylated recombinant human growth hormone designed for extended half-life and reduced injection frequency. It activates growth hormone receptors on target tissues, stimulating insulin-like growth factor-1 (IGF-1) production and promoting linear growth, protein synthesis, and lipolysis. The pegylation modification allows for less frequent dosing compared to standard somatropin.","oneSentence":"Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:19.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"},{"name":"Growth hormone deficiency in adults"}]},"trialDetails":[{"nctId":"NCT06927310","phase":"PHASE3","title":"The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2025-04-28","conditions":"Idiopathic Short Stature","enrollment":300},{"nctId":"NCT07309562","phase":"PHASE3","title":"The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2026-01-20","conditions":"Small for Gestational Age","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Inpegsomatropin Injection","genericName":"Inpegsomatropin Injection","companyName":"Xiamen Amoytop Biotech Co., Ltd.","companyId":"xiamen-amoytop-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}